Drug Search Results

BXCL-502

Alternative Names: BXCL-502, BXCL502, BXCL 502
Latest Update: 2025-03-11
Latest Update Note: News Article

Product Description

BXCL-502 is a drug candidate for the chronic treatment of agitation in patients with dementia. (Sourced from: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-third-quarter-2021-financial)

Mechanisms of Action: GPCR Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioXcel
Company Location: NEW HAVEN CT 06511
Company CEO: Vimal Mehta
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Dementia

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success

Recent News Events

Date	Type	Title
03/11/2025	News Article	BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
03/07/2025	News Article	BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
11/12/2024	News Article	BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia
10/29/2024	News Article	BioXcel Therapeutics to Present at ThinkEquity Conference

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions